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        Introduction 
  Progranulin (PGRN) is a glycosylated protein released by a 
variety of cells. It contains a signal peptide and 7.5 tandem 
repeats of highly conserved granulin motifs each with 12 cys-
teine residues (  Bateman et al., 1990  ;   Shoyab et al., 1990  ; 
  Bhandari et al., 1992  ;   Plowman et al., 1992  ;   He and Bateman, 
2003  ). PGRN is widely expressed (  Bhandari et al., 1993  ;   Daniel 
et al., 2000  ) and has been implicated in many processes, such 
as development, tumor proliferation, wound healing, and 
infl  ammation (  Bateman and Bennett, 1998  ;   He and Bateman, 
2003  ;   Ahmed et al., 2007  ). In peripheral tissues, extracellular 
proteases, such as elastase, were shown to be able to cleave 
PGRN into several GRNs (GRN A  –  F and paragranulin), which 
probably have separate functions (  Zhu et al., 2002  ;   He and 
Bateman, 2003  ). In models of wound healing, secreted leuko-
cyte protease inhibitor (SLPI) prevents PGRN processing 
through inhibition of elastase enzymatic activity and by binding 
PGRN and thus sequestering it from elastase (  Zhu et al., 2002  ; 
  He and Bateman, 2003  ). 
  Little is known about the role of PGRN in the central 
nervous system. PGRN is widely expressed during early 
neural development (  Daniel et al., 2003  ) but later on its ex-
pression becomes restricted to defi  ned neuronal populations, 
such as cortical and hippocampal pyramidal neurons and Pur-
kinje cells (  Daniel et al., 2000  ). It has been implicated in the 
sexual differentiation of the brain (  Suzuki and Nishiahara, 
2002  ). PGRN is up-regulated in activated microglial cells 
(  Baker and Manuelidis, 2003  ;   Baker et al., 2006  ;   Mackenzie 
et al., 2006  ;   Mukherjee et al., 2006  ) but not in astrocytes 
or oligodendrocytes. 
  Recently the interest in PGRN was raised because of the 
discovery of null mutations in the   PGRN   gene as a common 
cause of autosomal dominant tau-negative frontotemporal lobe 
dementia (FTLD;   Baker et al., 2006  ;   Cruts et al., 2006  ;   Gass 
et al., 2006  ;   Mukherjee et al., 2006  ;   Pickering-Brown et al., 
2006  ;   Bronner et al., 2007  ;   van der Zee et al., 2007  ). Further-
more, null mutations were also found in apparently sporadic 
patients (  Le Ber et al., 2007  ). The majority of FTLD-causing 
mutations in   PGRN   are predicted to cause functional null alleles 
with premature termination of the coding sequence followed 
by nonsense-mediated decay of the mutant mRNA (  Baker et al., 
2006  ;   Cruts et al., 2006  ). Therefore, haploinsuffi  ciency with 
R
ecently, mutations in the   progranulin   (  PGRN  ) gene 
were found to cause familial and apparently spo-
radic frontotemporal lobe dementia (FTLD). More-
over, missense changes in  PGRN   were identiﬁ  ed in patients 
with motor neuron degeneration, a condition that is re-
lated to FTLD. Most mutations identiﬁ  ed in patients with 
FTLD until now have been null mutations. However, it re-
mains unknown whether PGRN protein levels are reduced 
in the central nervous system from such patients. The ef-
fects of PGRN on neurons also remain to be established. 
We report that PGRN levels are reduced in the cerebro-
spinal ﬂ  uid from FTLD patients carrying a PGRN mutation. 
We observe that PGRN and GRN E (one of the proteolytic 
fragments of PGRN) promote neuronal survival and en-
hance neurite outgrowth in cultured neurons. These results 
demonstrate that PGRN/GRN is a neurotrophic factor 
with activities that may be involved in the development of 
the nervous system and in neurodegeneration.
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brain neuroblastoma) cells (  Daniel et al., 2000  ) and to inhibit 
apoptosis of tumor cells (  He et al., 2002  ;   Tangkeangsirisin et al., 
2004  ), the effects of PGRN on neurons have not been estab-
lished. To explore the neurotrophic potential of PGRN, we stud-
ied the effects of recombinant GRN E (aa 494  –  594 of PGRN, 
a functional proteolytic fragment of PGRN) and full-length 
PGRN (only lacking the first 18 aa, which code for the signal 
peptide) in monocultures of rat motor and cortical neurons. 
To reduce potential confounding effects from other growth 
factors, neurons were treated with GRN E or PGRN in serum-
free medium with no other recombinant growth factors added. 
Motor neurons isolated from the ventral spinal cord were seeded 
at low density allowing reliable quantifi  cation of survival by 
counting experiments (  Van Den Bosch et al., 2004  ;   Van Damme 
et al., 2007  ). GRN E was added to these cultures on day 1 in 
culture and was found to support neuronal survival in a dose-
dependent manner (  Fig. 2 A  ). This neurotrophic effect was 
still visible after 1 wk, a time point at which only a limited 
number of neurons in these serum-free and neurotrophin-free 
cultures survive (  Fig. 2 B  ). The maximal dose of GRN E 
increased neuronal survival by 64% on day 2 and by 101% 
on day 6. 
reduced PGRN-induced neuronal survival is thought to cause 
neurodegeneration. Missense mutations in   PGRN   have been 
identifi  ed as well. They were found in some patients with 
FTLD, with or without amyotrophic lateral sclerosis (ALS; 
  Spina et al., 2007  ;   van der Zee et al., 2007  ), and in rare ALS 
patients ( Schymick et al., 2007 ;  Sleegers et al., 2008 ). The patho-
genetic nature of these missense mutations remains to be 
demonstrated. It was recently shown that several of these 
missense mutations reduce the release of PGRN and thus 
also give rise to insuffi  cient availability of PGRN (  Shankaran 
et al., 2008  ). 
  Whether PGRN levels are indeed reduced in the central 
nervous system of patients with null mutations requires confi  rma-
tion and whether PGRN can directly affect neurons has not 
yet been shown. We therefore measured PGRN levels in the 
cerebrospinal fl  uid (CSF) from patients with PGRN mutations 
and controls and explored the potential neurotrophic effects of 
PGRN. The effects of exogenous PGRN and one of its proteo-
lytic fragments (GRN E) were studied in cortical neurons and 
spinal motor neurons, the two types of neurons relevant for 
FTLD and ALS. 
  Results and discussion 
  PGRN protein levels in the CSF from 
patients and controls 
  To measure PGRN protein levels, we developed an ELISA as-
say using a monoclonal PGRN antibody to coat 96-well plates, 
a polyclonal biotinylated PGRN antibody to detect the signal, 
and human recombinant PGRN as standard (  Fig. 1 A  ). PGRN 
protein was detectable in CSF and was measured in the CSF 
from three patients carrying the Ser82fs mutation in   PGRN   and 
from 24 controls. The optical densities were 0.08   ±   0.04 and 
0.23   ±   0.02 for patients and controls, respectively (P = 0.004). 
This corresponded to 2.2   ±   1.0 and 6.2   ±   0.6 ng/ml in patients 
and controls, respectively (P = 0.04;   Fig. 1 B  ). The clearly 
reduced levels in patients with the Ser82fs mutation are in 
agreement with the predicted nonsense-mediated mRNA decay 
caused by the premature translation termination, resulting in re-
duced protein levels. 
  Effect of PGRN on neuronal survival 
  Although PGRN was shown to induce proliferation of PC-12 
(rat adrenal gland pheochromocytoma) and SK-N-DZ (human 
  Figure 1.       Measurement of PGRN levels in the CSF by ELISA.   (A) Example 
of standard curve of recombinant PGRN (R 
2   = 0.99). (B) Mean PGRN 
levels in controls (  n   = 24) and patients with a Ser82fs mutation (  n   = 3; 
*, P = 0.04). Error bars show mean   ±   SEM.     
  Figure 2.       PGRN/GRN improves neuronal survival.   (A) Effect of GRN E 
on survival of motor neurons on day 2 in culture normalized to survival 
on day 1 (  n   = 5  –  11; R 
2   = 0.99). (B) Effect of GRN E on the survival of 
motor neurons at different time points in culture (  n   = 5  –  11; *, P   <   0.03). 
(C) Fluorescence (ﬂ   uorescein counts/1,000) emitted by cortical neurons 
seeded in different densities after loading with calcein-AM on day 2 in 
culture (  n   = 5; R 
2   = 0.99; inset shows neurons loaded with calcein; Bar, 
50   μ  m). (D) Effect of GRN E on ﬂ  uorescence of cortical neurons on day 2 
in culture normalized to untreated control (  n   = 8  –  15; R 
2   = 0.98). (E) Effect 
of PGRN on survival of motor neurons (  n   = 6  –  10; R 
2   = 0.95). (F) Effect of 
PGRN on survival of cortical neurons (  n   = 9; R 
2   = 0.95). Error bars show 
mean   ±   SEM.     39  PROGRANULIN IS A NEUROTROPHIC FACTOR   •   VAN DAMME ET AL.
survival and axonal outgrowth, respectively, supports the hypoth-
esis that different GRNs and their precursors may have distinct 
biological functions (  Zhu et al., 2002  ). 
  Recently, PGRN-deficient mice have been generated 
( Kayasuga  et  al., 2007  ). These mice develop normally and do 
not show behavioral or motor abnormalities until 11 wk of age. 
However, it remains to be seen whether these animals develop 
axonal loss or neurodegeneration as they age. 
  Our results demonstrate that PGRN/GRN is a neurotrophic 
factor that enhances neuronal survival and axonal outgrowth. 
It supports the hypothesis that a relative lack of PGRN in pa-
tients with PGRN mutations may alter the integrity of neurites 
and lead to neurodegeneration. Mechanisms other than the lack 
of neurotrophic effect resulting from PGRN shortage may play 
a role in PGRN-associated neurodegeneration as well. In a 
recent study, PGRN knockdown was found to induce caspase-
dependent cleavage of TDP-43 with accumulation of TDP-43 
fragments (  Zhang et al., 2007  ), similar to what is seen in FTLD 
and ALS (  Neumann et al., 2006  ). 
 Although insuffi  cient trophic support for neurons has been 
an appealing hypothesis for the pathogenesis of neurodegenera-
tive disorders and the premise for many therapeutic strategies 
(  Vande Velde and Cleveland, 2005  ), PGRN is the only neuro-
trophic factor identifi  ed to cause human disease through null 
mutations and haploinsuffi  ciency. Therefore, it is warranted 
to investigate the therapeutic potential of PGRN for neuro-
de generative  disorders. 
 Similar results were obtained in cortical neurons. To quan-
tify survival of cortical cultures, a calcein-acetyoxymethyl (AM) 
assay was used (  Bozyczko-Coyne et al., 1993  ;   Lin et al., 2001  ). 
This assay proved to reliably refl  ect the number of living cells 
in culture, as shown in   Fig. 2 C  . To assure that the signal ob-
tained was in the linear part of the assay, 10,000 cells per 
well were seeded for survival experiments. GRN E improved 
survival of cortical neurons by 41.4% (  Fig. 2 D  ), confi  rming 
that the GRN E proteolytic fragment of PGRN has neuro-
trophic properties. 
  The full-length precursor, PGRN, exerted similar neuro  tro-
phic properties, both in motor and cortical neurons ( Fig. 2, E and F ). 
The maximal effect observed was a 38.5 and 22.0% increase in 
neuronal survival for motor and cortical neurons, respectively. 
  The effects of GRN E and PGRN on motor and cortical 
neurons were dose-dependent and the ED  50   (0.1 – 3  ng/ml)  ap-
proximated the ED  50   of the proliferative effects on cell lines 
reported previously (  Zhou et al., 1993  ). 
  In wound healing, SLPI was shown to block PGRN pro-
cessing both by inhibiting the proteolytic activity of elastase 
and by direct binding to PGRN (  Zhu et al., 2002  ). We there-
fore investigated the effect of SLPI on the effects of PGRN 
in neuronal cultures and found that coadministration of SLPI 
abolished the neurotrophic effects of PGRN on both motor 
neurons and cortical neurons (  Fig. 3, A and B  ). This suggests 
that proteolysis of PGRN is needed for it to have neurotrophic 
effects. Alternatively, because of its dual actions, SLPI may 
scavenge PGRN and thus keep PGRN from exerting its neuro-
trophic effect. 
  Effect of PGRN on neurite outgrowth 
  To study the effect of PGRN/GRN on neurite outgrowth, motor 
and cortical neuronal cultures were treated with GRN E or 
PGRN on day 0 and cells were stained for neurofi  lament heavy 
chain (NF-H) after 24 h. This allowed us to quantify the size of 
the soma and the length of neurites present (  Fig. 4, A  –  D  ). GRN E 
and PGRN had no effect on the size of the cell soma. Both 
molecules increased the maximal neurite length, an effect that 
was especially apparent after the treatment of cells with full-
length PGRN (  Fig. 4, E and F  ). Again, the neurite outgrowth  –
  stimulating effect of PGRN was inhibited by SLPI (  Fig. 4 F  ). 
  From these experiments, it is clear that neurite length is 
mainly affected by PGRN and, to a lesser extent, by GRN E, 
whereas the opposite was true for the effect on neuronal sur-
vival. This differential effect of GRN E and PGRN on neuronal 
  Figure 3.       Inhibition of PGRN by SLPI abolishes its neurotrophic properties.   
(A and B) Effect of SLPI (ng/ml) on the neurotrophic properties of PGRN 
(ng/ml) in motor neurons (A;   n   = 3  –  4; *, P   <   0.001) and cortical neurons 
(B;   n   = 6; *, P   <   0.01). Error bars show mean   ±   SEM.     
  Figure 4.       Effect of PGRN/GRN on soma size and neurite outgrowth.   
(A  –  D) NF-H staining of motor neuron (A and B) and cortical culture 
(C and D) treated with GRN E (B), PGRN (D), or control (A and C; Bar, 
50   μ  m). (E and F) Effect of 100 ng/ml GRN E or PGRN (in the absence 
and presence of 100 ng/ml SLPI) on soma size (E) and maximal neu-
rite length (F;   n   = 109  –  476; *, signiﬁ  cantly different from control [P   <   
0.001]; #, signiﬁ  cantly different from GRN E [P   <   0.03]). Error bars 
show mean   ±   SEM.     JCB • VOLUME 181 • NUMBER 1 • 2008  40 
more than 100 neurons per experimental condition were measured on the 
obtained digital pictures using Lucia imaging software (version 4.60; 
  Laboratory Imaging). 
  Materials and statistics 
  Media and additives were obtained from Invitrogen. All other chemicals 
were obtained from Sigma-Aldrich. Partial recombinant human PGRN (aa 
494  –  594, coding for GRN E and ﬂ  anking regions) was obtained from Ab-
nova Corporation. Full-length recombinant human PGRN (aa 18  –  593) was 
obtained from R  &  D Systems. NF-H and GFAP antibodies were obtained 
from Sigma-Aldrich. NeuN antibody was obtained from Millipore and anti-
oligodendrocyte marker 04 was obtained from R  &  D Systems. Alexa-
labeled secondary antibodies were obtained from Invitrogen. 
  Mean data are shown as mean   ±   SEM and Student  ’  s   t   tests were 
used to calculate signiﬁ  cance. When more than two groups were com-
pared, a one-way analysis of variance with Tukey-Kramer multiple compar-
isons was used. 
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  Materials and methods 
  PGRN ELISA 
  CSF samples from three FTLD patients caused by null mutations in PGRN 
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local ethical committee. The PGRN levels were measured by ELISA. To do 
so, 96-well plates were coated with monoclonal anti-PGRN antibody (R  &  D 
Systems) blocked with 1% BSA before samples and standard (recombinant 
human PGRN; R  &  D Systems) were loaded. Afterward, bound PGRN was 
detected using biotinylated polyclonal anti-PGRN antibody (R  &  D Systems), 
avidin  –  biotin  –  peroxidase complex, and ortho-phenylenediamine. Absor-
bance was measured at 490 nm. Western blots stained with the antibodies 
used in this assay showed that only recombinant PGRN was recognized, 
not recombinant GRN E or PGRN cleavage products obtained by elastase 
treatment (1 U/ml for 30 min at 25  °  C; Athens Research   &   Technology). 
  Neuronal cultures 
  Monocultures of cortical and motor neurons were prepared from 14-d-old 
Wistar rat embryos as previously described (  Van Damme et al., 2003, 
2007  ;   Van Den Bosch et al., 2004  ) and plated in culture dishes (40,000 
cells per dish for spinal cultures) or 96-well plates (10,000 cells per well) 
coated with poly-  L  -ornithine and laminin. Ventral spinal cords were dis-
sected from rat embryos and dissociated enzymatically and mechanically. 
A motor neuron  –  enriched neuronal population was obtained by centrifuga-
tion on a 6.5% Optiprep cushion. For cortical cultures, the cortex was dis-
sociated by trypsinization and trituration but the density centrifugation was 
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sodium bicarbonate, 3.6 mg/ml glucose, 20 nM progesterone, 5   μ  g/ml 
insulin, 0.1 mM putrescine, 0.1 mg/ml conalbumin, 30 nM sodium selenite, 
100 U/ml penicillin, 100   μ  g/ml streptomycin, 5% chick embryo extract, 
2% and horse serum. No horse serum was added in the serum-free me-
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7% CO  2   humidiﬁ  ed incubator at 37  °  C. Most cells in culture stained posi-
tive for NF-H and neuron-speciﬁ  c nuclear protein (NeuN) on day 1 after 
seeding. Few cells stained positive for the astroglial marker glial ﬁ  brillary 
acidic protein (GFAP) or the oligodendroglial marker O4. 
  Neuronal survival 
  The survival of monocultures of motor neurons was quantiﬁ  ed by direct 
counting of unﬁ   xed cells under phase contrast, as previously described 
(  Van Den Bosch et al., 2004  ). Neurons in a marked area of 1 cm 
2   were 
counted before (on day 1 after seeding) application of PGRN/GRN or 
control. After counting on day 1, the medium was replaced by serum-free 
medium. Because partial recombinant human PGRN (coding for GRN E) 
was dissolved in buffer containing reduced glutathione, this was added to 
the corresponding controls as well. The relative survival was calculated as 
the number of cells on day 2 or 6 in culture divided by the number of cells 
on day 1. 
  Survival of cortical neurons was quantiﬁ  ed using a calcein assay 
(  Bozyczko-Coyne et al., 1993  ;   Lin et al., 2001  ). On day 1 in culture, neu-
ronal cultures seeded in 96-well plates were treated with PGRN/GRN or 
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1 h at 37  °  C. After replacement of the medium with PBS, ﬂ  uorescence was 
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After subtraction of background signal from wells without cells, the values 
obtained were normalized to untreated control wells. For every condition, 
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clonal), and O4 (1:500; mouse monoclonal) overnight. The appropriate 
Alexa 
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the stain. 
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